The association between short-term response and long-term survival for cervical cancer patients undergoing neoadjuvant chemotherapy: a system review and meta-analysis

新辅助化疗对宫颈癌患者短期疗效与长期生存率的影响:系统评价和荟萃分析

阅读:1

Abstract

Controversy exists regarding whether a short-term response has an impact on the long-term survival of cervical cancer patients undergoing neoadjuvant chemotherapy (NACT). This study was designed to identify the predictive role of an early response by pooling the results of previous studies. The PubMed and Embase databases were searched through July 2016, and the associations between an early response and disease-free survival (DFS) were pooled by hazard ratio (HR) using random effects models. Six studies involving 490 cervical cancer patients, with 336 responders and 154 non-responders, were finally included in the meta-analysis. The HR for 1-year DFS between early responders and non-responders was 0.25 (95% CI 0.10-0.58, P = 0.001). The HRs for 2-, 3-, 4-, and 5-year DFS were 0.28 (95% CI 0.15-0.56), 0.27 (95% CI 0.16-0.45), 0.29 (95% CI 0.17-0.50) and 0.33 (95% CI 0.20-0.54), respectively. No obvious heterogeneity was found among the studies, with I(2) = 0, and a sensitivity analysis showed that all pooled results were robust with logHR confidence limits < 0. An early response was associated with DFS, and responders achieved a significantly higher survival rate than non-responders. This finding should be validated in future prospective studies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。